COLCHICORT Trial
The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors.
Read Article
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurements. SUA levels had NO ASSOC. w/ all-cause mortality, disability-free survival, CV Dz, MACE, cancer mortality, cognitive decline, or dementia. In females, low SUA https://t.co/VY6NJsetW9
Dr. John Cush @RheumNow( View Tweet )
Target trial emulation looked at CV (MACE) events in 18,120 propensity score–matched adults with gout starting allopurinol who were given NSAIDs or colchicine for prophylaxis. MACE & CV death were signif. higher w/ NSAIDs vs Colchicine (HRs of 1.56 and 2.50), respectively. https://t.co/0T8slmPBng
Dr. John Cush @RheumNow( View Tweet )
COLCHICORT Trial
The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors.
https://t.co/CC2yVRXbD5 https://t.co/ebLa3FUbGR
Links:
Dr. John Cush @RheumNow( View Tweet )
Gout: Highlights from APLAR 2025
Dr. Sheila Reyes, The Philippines, reports on highlights and takeaways from lectures on the treatment of gout from the APLAR 2025 Congress in Fukuoka, Japan.
https://t.co/Fxd3MBUYrT https://t.co/gKjHlJXttT
Dr. John Cush @RheumNow( View Tweet )
Dr. Binit Vaidya aptly poses this slide on the gout paradox: evidence-based T2T tx exist yet many still have uncontrolled dse.
How can we close this gap?
- address barriers to tx adherence
- motivation
- px education
- multidisciplinary approach to px care
@rheumnow #APLAR25 https://t.co/IEn9PMAxH5
sheila @RHEUMarampa( View Tweet )
Colchicine for #gout patients with CV risk:
- since it has a purely anti-inflammatory effect, risk of acute CV events in pts w/ high CV risk is reduced.
vs. NSAIDs/steroids, colchicine remains to be a safer option for gout prophylaxis
@rheumnow #APLAR25 https://t.co/WgfTcIleMd
Links:
sheila @RHEUMarampa( View Tweet )
SGLT2 inhibitors exert their anti-inflammatory effects by inhibiting activation of the NLRP3 inflammasome.
Secondary analyses of RCTs show that SGLT2is can reduce the risk of incident #gout
@RheumNow #ACR25 https://t.co/IWgyDYEQoZ
Links:
sheila @RHEUMarampa( View Tweet )
Gout Education Card for Patients - Info & Rules #1
https://t.co/uppST8OBLZ https://t.co/3Ry3erNJCL
Dr. John Cush @RheumNow( View Tweet )
Gout Education Card for Patients - Diagnosis & Management #2 https://t.co/uppST8OBLZ https://t.co/sLF5WPeuA5
Dr. John Cush @RheumNow( View Tweet )
Sjögren's Graduates (8.22.2025)
Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.
Read Article
A New RA Approval (8.1.2025)
Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.
Read Article
RA & GOUT? S. Korean study of 34,356 new RA pts vs 103,068 controls. RA had 2.7 X higher risk of gout vs non-RA. Seropos & Seroneg equal incr risk (aHR 2.8 & 2.6), slightly higher in SPRA(aHR 1.07). RA on b/tsDMARDs had lower risk (aHR, 1.93) vs Untreated (aHR, 2.78). https://t.co/P0oqq5bVnq
Dr. John Cush @RheumNow( View Tweet )
NEJM images: 55-year-old man with metastatic squamous-cell lung cancer Hx& 6-wk Hx firm, painful swelling RToe1 & RDIP3 w/ ulceration. Xray showed lytic lesions due to acrometastases - rare bony metastases distal to elbow or knee, that may may mimic gout or osteomyelitis https://t.co/1Fh1Cp9dm9
Dr. John Cush @RheumNow( View Tweet )
NHANES, Numbers, & Risk (7.18.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com along with interesting case questions from "Ask Cush Anything".
Read Article
Rheums! Question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast.
https://t.co/HsqM9xLNtP https://t.co/voONsOLeSK
Dr. John Cush @RheumNow( View Tweet )
Hmmm Really? (7.11.2025)
Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
Read Article
ICYMI: Proinflammatory Diet Increases Gout Risk
MedPage Today
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated. Data from the two iterations of the Nurses' Health Study, in which more than 170,000 women were followed for more than two decades, indicated that diets scoring high on the Empirical Dietary
Read Article
Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990). From 1990 to 2021, the prevalence of MSK Dz in PMW significantly risen, especially for RA, OA, and gout. https://t.co/HdkopkxLdv https://t.co/wsGhg0P1tL
Dr. John Cush @RheumNow( View Tweet )
New ideas in gout management
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX
Dr. John Cush @RheumNow( View Tweet )
Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1.51) and gout (OR 1.81) - more so in males > females. Little effect of age, country, study type, type of alcohol, Dx criteria in regression analyses. https://t.co/NSYTppcKzV
Dr. John Cush @RheumNow( View Tweet )
Nurse-Led Treat-to-Target Clinics
EurekAlert!
New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.
Read Article
The ‘iron fist’ of haemochromatosis arthropathy, and other key features:
Patrick Kiely #EULAR2025 @RheumNow https://t.co/grs1Tq3GAk
Links:
David Liew @drdavidliew( View Tweet )
1st #recommendations for
#Hemochromatosis #arthropathy
#psuedogout
#CPPD
#calcium #pyrophosphate #arthritis
#EULAR2025 #Recommenadations II
@RheumNow @eular_org https://t.co/AnE4T2wYoa
Janet Pope @Janetbirdope( View Tweet )
URAT1 inhibitors look like the way to go in Gout!
Presented in multiple abstracts at #EULAR2025
Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300
Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302
Ph 2b RCT of SAP-001 Refractory Gout +/-
Aurelie Najm @AurelieRheumo( View Tweet )
Recent Blogs
